Abstract We compared the frequency of gastrointestinal (GI) pathogen detection in an oncology patient population by two multiplexed molecular assays, the Luminex xTAG® Gastrointestinal Pathogen Panel (GPP, which identifies 14 GI pathogens) and the BioFire Gastrointestinal Panel (BFGP, which identifies 22 GI pathogens). We additionally reviewed the clinical characteristics of patients tested with both panels. A total of 200 prospectively collected and 81 archived stool samples were tested by both panels. In the prospective cohort, the GPP and BFGP identified a pathogen in 33.5% [95% confidence interval (CI): 27.3-40.35%] and 39.6% (95% CI: 33.0%-46.6%) of samples, respectively (p = 0.25). The BFGP detected significantly more pathogens than the GPP (p = 0.038), with 21.3% of samples positive for targets only detected by the BFGP. The concordance between the assays was very good at 91.1% (κ = 0.8, 95% CI: 0.7-0.9) when considering only pathogens detected by both assays. The most frequent pathogens detected were Clostridium difficile, norovirus, Campylobacter, and Salmonella species. On the archived samples, the BFGP was positive in 92.6% of samples but detected more pathogens than the GPP (86 vs. 97, p = 0.033), including both targets unique to the BFGP and targets common to both panels. A pathogen was more frequently detected in patients with hematological malignancies than solid tumors and in ambulatory patients compared to hospitalized patients, but these differences were not statistically significant. Overall, the detection rates were similar for both the GPP and the BFGP, and the latter detected more than one pathogen in additional patients. The impact of increased detection of GI pathogens by multiplexed panels on the clinical care of oncology patients will require further investigation.
Introduction
Infectious gastroenteritis is a major cause of morbidity and mortality worldwide, with an estimated 2 billion annual cases. Approximately 179 million annual cases of acute gastroenteritis are estimated to occur in the United States, resulting in 474,000 hospitalizations and 5000 deaths [1] . Chemotherapy treatment for oncology patients is well known to be associated with various side effects, in particular toxicity to the gastrointestinal (GI) tract. GI toxicity can manifest as mucositis, a painful inflammatory condition that affects all parts of the GI tract [2] . Mucositis causes breaches in the integrity of the bowel and subsequently increases the risk of secondary infections and provides a nidus for systemic infections [2, 3] . In addition, these patients have compromised immune systems and are, therefore, at a higher risk of serious complications from gastroenteritis [4, 5] . To further confound oncology patient management, frequent side effects of chemotherapy include nausea and vomiting, making it difficult to clinically distinguish between infectious and non-infectious sources of symptoms [6] .
In recent years, large, syndromic panels for the detection of GI pathogens have received clearance by the U.S. Food and Drug Administration (FDA) for use in the diagnosis of infectious diarrhea. Two of these assays are the Luminex xTAG® Gastrointestinal Pathogen Panel (GPP; Luminex Corporation, Toronto, Canada) and the BioFire Gastrointestinal Panel (BFGP; BioFire, Inc., Salt Lake City, Utah). The Luminex GPP is FDA-cleared for 14 targets (eight bacteria, three viruses, and three parasites), while the BFGP includes 22 FDA-cleared targets (13 bacteria, five viruses, and four parasites). A few studies have evaluated the performance of these assays in a variety of patient populations, such as immunocompetent hosts, hospitalized patients, outpatients settings, pediatric oncology patients, and kidney transplant recipients [7] [8] [9] [10] [11] . Fewer studies have performed head-tohead comparisons of these multiplexed panels [9, 10] and, to date, no studies have focused on their performance in a primarily adult, oncology, and hematopoietic stem cell transplant (HSCT) recipient patient population.
We performed a study at Memorial Sloan Kettering Cancer Center (MSKCC), a 465-bed tertiary cancer care center in New York City. The objectives of this study were to compare the frequency of GI pathogen detection in diarrheal illness in an oncology (solid tumors and hematologic malignancies) patient population by two multiplexed molecular assays and to determine the characteristics of patients with GI pathogens detected by either panel.
Materials and methods

Study design
A total of 200 consecutive stool samples from hospitalized and ambulatory adult and pediatric patients were collected over 4 weeks (September to October 2014) and tested by the GPP as part of the routine clinical testing. The samples were stored at 4°C and tested by the BFGP within 7 days. An additional 81 archived samples, initially identified as positive for a GI pathogen by the GPP, were selected for testing by the BFGP. Samples were selected to cover all available GPP viral, bacterial, and parasite targets, and included samples for every week since the use of the GPP test was implemented for routine clinical care (March 2014). Archived specimens were stored at −80°C following routine clinical testing by the GPP for up to 6 months prior to testing by the BFGP.
Multiplexed GI panels
The GPP panel includes the following targets: Clostridium difficile, Shigella, Escherichia coli O157:H7, Salmonella, Campylobacter, Shiga toxin-producing E. coli (STEC), enterotoxigenic E. coli (ETEC), Vibrio cholerae, norovirus GI/ GII, rotavirus A, adenovirus F40/41, Cryptosporidium spp., Giardia, and Entamoeba histolytica. The BFGP includes all targets listed above for the GPP plus Plesiomonas shigelloides, Vibrio species (parahaemolyticus, vulnificus), enteroaggregative E. coli (EAEC), Shigella/enteroinvasive E. coli (EIEC), enteropathogenic E. coli (EPEC), Yersinia enterocolitica, astrovirus, sapovirus, and Cyclospora cayetanensis.
Testing by the GPP assay was performed per the manufacturer's instructions on raw, unpreserved stool specimens. For the BFGP, the following modifications to the manufacturer's instructions were made: (1) samples were tested after storage for up to 7 days at 4°C or after storage at −80°C for up to six months and (2) samples were not collected in Cary-Blair media, the FDA-cleared specimen type. To best approximate the volume and dilution that occurs when stool samples are collected in Cary-Blair media (1 g or 1-5 mL into 9-15 mL of media, depending on the manufacturers), raw stools were first thawed (if frozen) and diluted (1:4, stool:water) into PCRgrade water. Testing was then performed per the manufacturer's instructions, using 200 μL of stool sample.
Discordant result analysis
Additional testing was performed to investigate targets with greater than five samples with discordant results between the two panels. Discordant analysis was performed for C. difficile with the Cepheid GeneXpert C. difficile assay and for noroviruses with a lab-developed qRT-PCR assay [12, 13] .
Demographic and clinical data
Medical records were reviewed to determine the clinical characteristics of patients enrolled in the prospective study. The following information was extracted directly from the medical records: age, sex, underlying malignancy, hospital length of stay (LOS), GI symptoms, white blood cell count, mortality, recent antibiotics and chemotherapy treatment (within 30 days of testing), and transplant status.
Statistics and data analysis
Assay concordance and 95% confidence intervals (CIs) were calculated using GraphPad Prism (version 7.01). Analysis was performed with a chi-square test or Fisher's exact probability test for comparisons of proportions between two groups. A pvalue of <0.05 was considered significant.
Results
A total of 200 consecutive samples were tested by both multiplex molecular panels. Three samples collected during the study period were from hospital employees and, therefore, excluded from further analysis. Overall, 197 samples from 170 patients were included in the final analysis, with 24 samples from 20 pediatric patients (Table 1 ). The GPP identified 66 positive samples, for a detection rate of 33.5% (95% CI: 27.3-40.35%), while the BFGP identified 78 positive samples for a detection rate of 39.6% (95% CI: 33.0%-46.6%). Four patients with samples positive for more than one pathogen were identified by both the GPP and the BFGP. The BFGP detected more than one pathogen in an additional 13 patients that were previously unrecognized, primarily due to the additional detection of EPEC and EAEC. There were no statistically significant differences in the overall detection rates between the two panels (p = 0.25). However, the BFGP detected significantly more pathogens than the GPP (100 vs. 72, p = 0.038), with 21.3% (n = 22) of the increased detection due to targets that are not included on the GPP (Table 1) .
There were 32 discordant specimens: 20 specimens had completely discordant results (i.e., negative by one panel but positive by the other panel; e.g., negative by GPP but positive for C. difficile by BFGP) and 12 specimens had partially discordant results (i.e., both panels were positive for different or additional pathogens; e.g., positive for STEC by GPP and positive for astrovirus by BFGP) ( Table 1 ). Fourteen samples overall were completely (n = 11) or partially (n = 3) discordant for pathogens common to both panels. The concordance between the assays was very good at 91.1% (κ = 0.8, 95% CI: 0.7-0.9) when considering only pathogens detected by both assays, with the most frequently identified pathogens being C. difficile, norovirus, Campylobacter, and Salmonella species ( Table 1) .
The performance of the two assays was further compared by testing archived positive samples initially tested by the GPP assay as part of routine clinical care. This analysis was performed primarily to estimate the frequency of the additional BFGP targets in these samples. Of the 81 samples tested, the BFGP was positive in 75 samples (92.6%) but detected 97 pathogens compared to 86 pathogens by the GPP ( Table 2 ). The BFGP detected ten additional pathogens not included on the GPP panel and nine pathogens common to both panels, while the GPP detected eight pathogens not detected by the BFGP (Table 2) . Two or more pathogens were detected in four samples by both methods. The BFGP detected more than one pathogen in an additional 16 samples, with 50% of those samples positive for EPEC/EAEC (Table 2) .
Overall, norovirus and C. difficile were more frequently found individually, whereas ETEC, EAEC, and EPEC were more frequently found along with another pathogen (data not shown). In particular, EAEC was frequently associated with Shigella, STEC, and ETEC, while EPEC was most frequently associated with Shigella, Campylobacter, ETEC, and EAEC (data not shown). These associations, however, were not statistically significant (p > 0.05).
A high number of samples with discordant results (n > 5) between the two panels was noted for C. difficile and norovirus (p < 0.001). The Xpert C. difficile assay (Cepheid, Inc., Sunnyvale, CA) was used to arbitrate the discordant C. difficile results for both the prospective and archived samples. All 12 discordant samples were positive by the Xpert PCR assay, confirming the positive BFGP results ( Table 3) . The Xpert C. difficile real-time PCR cycle threshold (C t ) values (a surrogate of C. difficile bacterial loads) were further reviewed for all positive samples (concordant and discordant samples). There was a significant difference (p < 0.05) in the mean C t value between samples positive for C. difficile by both panels (C t 26.2) compared to the mean C t value for samples positive by the BFGP only (C t value = 28.6), suggesting that differences observed could be due to a higher detection STEC Shiga toxin-producing E. coli; ETEC enterotoxigenic E. coli; EAEC enteroaggregative E. coli; EIEC enteroinvasive E. coli; EPEC enteropathogenic E. coli; n/a not applicable (target not included on panel)
*Twenty-four samples from pediatric patients rate of the BFGP at low bacterial loads (data not shown). There were seven discordant norovirus results between the BFGP and the GPP. Five samples were positive by the GPP only and two were positive by the BFGP only. The third PCR assay confirmed 5 of the 7 GPP results (two negative, three positive) and 2 of the 7 BFGP results (two negative) ( Table 3) . The demographic and clinical characteristics of 170 patients prospectively enrolled and tested by both panels were reviewed. The results are summarized in Table 4 . The median patient age was 54.5 years (range 3-86 years), with 11.8% of patients under the age of 18 years, 54.7% female, 51.2% with a diagnosis of hematologic malignancy (e.g., leukemia or lymphoma) or receipt of an HSCT, and 51.5% with recent chemotherapy treatment (within 30 days prior to GI panel testing). A total of 120 patients (70.6%) were hospitalized at the time of testing, with 17.5% in the intensive care unit (ICU) and 50% having received antibiotics within 30 days of GPP testing. Diarrhea was recorded in 78.5% of all patients and 43% of patients with diarrhea had a positive GPP or BFGP result. A pathogen was detected in more than 50% of patients with GI graft versus host disease (54.5%) or colitis on imaging (62.5%). The median hospital LOS was 11.5 days (95% CI: 8-17 days), with an all-cause mortality rate of 5.9%. The median LOS was shorter for patients positive for a GI pathogen (6 days, 95% CI: 4-14 days) compared to patients with no GI pathogens detected (16 days, 95% CI: 10-24 days) (p < 0.0001).
There were no significant differences between the frequency of positive results of patients with hematologic malignancies or HSCT recipients or patients with solid tumors (47.1% vs. 37.3%, p = 0.21). The distribution of pathogens common to both panels was similar in both groups of oncology patients, with C. difficile as the most frequently identified pathogen. Unique to the BFGP, EPEC was the second most frequent pathogen (Table 5 ). More Salmonella and Campylobacter infections were detected in patients with hematologic malignancies or HSCT recipients, but the differences were not statistically significant (p = 0.06). A small percentage (11.8%) of patients was under the age of 18 years and, as with the adult patients, C. difficile was the most frequently identified pathogen. The second most frequently identified pathogen by the BFGP was EPEC in four pediatric patients. Detection rates by both panels were similar for all common targets in all patient groups (Table 5) .
A review of the clinical characteristics of patients positive for more than one pathogen showed that these infections were not associated with more severe disease, as measured by LOS, ICU admission, 30-day mortality, antibiotics use, or GI symptoms, including nausea, vomiting, diarrhea, fever, or abdominal pain (data not shown).
Discussion
To the best of our knowledge, our study is the first to compare the frequency of GI pathogens detection by the Luminex xTAG® Gastrointestinal Pathogen Panel (GPP) and the BioFire Gastrointestinal Panel (BFGP) in both adult and pediatric oncology patients exclusively. Our data show that the two assays had similar detection rates, with an overall concordance of greater than 90% for targets common to both assays, similar to other studies performed in different patient populations [9, 14] . The most frequent GI pathogens in our oncology patient population were C. difficile, norovirus, Campylobacter, and Salmonella species. The high rate of C. difficile detection was expected in this population of patients who are at increased risk for both C. difficile infection and asymptomatic C. difficile carriage, given their frequent and prolonged exposure to healthcare environments and antibiotics usage. Unlike other studies where sapovirus and astrovirus were detected in several patients, only one patient in our cohort was positive for astrovirus [9, 14] . This difference may reflect differences in patients tested, as both viruses are more frequently detected in pediatric patients, which only represented ∼12% of our patient cohort. A larger study over an extended time frame could provide a different pathogen epidemiology. There were some notable differences between the two panels. The Luminex GPP assay showed a lower detection rate for C. difficile. On average, the corresponding Xpert C. difficile C t values of the negative GPP samples were higher than those of the samples positive by both panels, suggesting that the negative samples likely had a lower bacterial load. This result is in contrast with the study by Gu et al. conducted GI Gastrointestinal; HSCT hematopoietic stem cell transplant; GVHD graft versus host disease; WBC white blood cells; N/A not applicable among pediatric oncology patients showing a higher detection rate for C. difficile by the Luminex assay [14] . Additional discordant samples were observed for norovirus results. One previous report noted poor specificity of the Luminex GPP assay for norovirus [9] . In that study, discrepant norovirus results were attributed to lot-specific problems and corrected upon retesting with a new lot of reagents [9] . In our data set, a third norovirus-specific RT-PCR was used to confirm the presence of norovirus identified by the GPP and the BFGP. Resolution of discordant results showed that the overall performance of both assays for norovirus was equivalent. Diarrhea is a frequent symptom in cancer patients and differentiating between infectious or non-infectious causes requires laboratory testing. Similar to our study, Mhaissen et al. reviewed the clinical characteristics of pediatric oncology patients positive by the GPP and the BFGP [10] . In our study, 78.5% of patients had diarrhea and 43% of these patients had a pathogen identified by the multiplexed GI panels. In contrast, Mhaissen et al. [10] showed that 95% of patients in the pediatric oncology population had diarrhea and 60-65% of patients were positive for a GI pathogen, which is similar to data from our small pediatric cohort. Although the presence of a pathogen alone does not imply symptoms causation, the results provided by these GI panels along with other clinical data may help inform clinical decisions.
A pathogen was more frequently detected in patients with hematological malignancies than solid tumors and more frequently in ambulatory patients than in hospitalized patients, although the differences were not statistically significant. Of interest, both Salmonella and Campylobacter species were detected more frequently in adult patients with hematologic malignancies, but the overall numbers were too small to draw significant conclusions. There was no significant correlation between a positive multiplex panel and ICU stay, 30-day mortality, or number of symptoms, but there was a significant correlation between a negative GI panel and a longer LOS. However, given the complex presentation of these more critically ill cancer patients who are often admitted for extended periods of time, the observed differences in LOS could be a result of multiple factors not measured in this study. More than one pathogen was more frequently detected by the BFGP, largely due to the detection of EPEC or EAEC, which are not detected by the GPP assay. The increased detection of diarrheogenic E. coli and their recovery in mixed infections is consistent with previous reports and unlikely to represent false-positive results or contamination, although these possibilities were not investigated further in our study [7, 9] . Further review of the clinical characteristics of patients with multiple pathogens detected did not reveal more severe disease than in patients with monomicrobial infections. The increased detection of more than one pathogen with the BFGP indicates that the presence of multiple pathogens in diarrheal stool samples may be underestimated. While these diarrheogenic E. coli are known to be associated with GI symptoms in patients [15] , their role in causing polymicrobial infections in oncology patients remains unclear. However, our study is limited by the small number of patients positive for more than one pathogen and larger studies may reveal a stronger association with disease severity.
Our study has some limitations. First, this is a singlecenter study in an oncology patient population and, as such, our results may not be applicable to other centers or patient populations. However, as the number of immunocompromised cancer patients continues to increase and treatment options improve, these patients tend to survive longer and remain a significant part of our healthcare system [16] . Therefore, the data presented here should be of interest to a wider audience. Second, discordant analysis was only performed for C. difficile and norovirus, as these were the most frequently identified targets. While assays specificity or possible contamination may explain the few differences observed, the sensitivity and specificity of these two panels have been previously evaluated and, although comparable, are not expected to be identical [9, 14] . Finally, the off-label testing and the testing of samples frozen for a few months may have negatively impacted the detection of pathogens by the BFGP, although the overall detection rate remained higher than that of the GPP.
Conclusion
In conclusion, multiplexed, molecular panels are new technologies that are changing the frequency and distribution of gastrointestinal pathogens in immunocompromised oncology patients. Further outcome studies on the impact of tests results in various patient populations, including cancer patients, are needed to determine the value of these panels on patient care, antimicrobial stewardship, and infection control programs.
